This study, led by a team from Cornell University, looked at the molecular features of fibrolamellar carcinoma (FLC), a rare liver cancer that mainly affects teenagers and young adults. Until now, most studies analyzing biological data from fibrolamellar tissue have examined tumors in bulk, mixing together all the different cell types found in a tumor. That made it difficult to determine which specific cell types were responsible for specific genetic and molecular changes.
To solve this problem, the researchers used advanced genomic technologies called single-nucleus ATAC-seq and single-nucleus RNA-seq. These methods allow scientists to study individual cells and identify:
- Which genes are active in specific cells
- Which regions of DNA are accessible and regulating those genes
- Which cell types are producing specific molecular signals.
What They Found
The study showed that many molecular features linked to FLC actually come from different cell types within the tumor, not just the cancer cells themselves. Each tumor contains a complex ecosystem of:
- Cancer cells
- Blood vessel cells
- Immune cells
- Fibrosis-producing support cells (stellate cells and fibroblasts).
The researchers identified:
- Cell-type-specific chromatin changes (changes in how DNA is organized and regulated).
- Key microRNAs that are active in different cell populations. For example, some microRNAs were enriched in tumor cells, while others came primarily from blood vessel or stromal cells.
- Important transcription factor networks, including one involving CREB3L1, that may help drive disease biology.
- Large regulatory DNA regions called super-enhancers near genes already known to be highly expressed in FLC, including CDH11 and SLC16A14.
Key Implications
The biggest contribution of the paper is that it creates a high-resolution map of how different cell types in FLC are behaving. Instead of viewing the tumor as a single mass of cancer cells, the study shows that the surrounding microenvironment plays a major role in shaping the disease.
This information could help researchers:
- Discover new drug targets in both tumor cells and the surrounding tumor microenvironment.
- Better understand how the characteristic DNAJB1-PRKACA fusion drives FLC biology.
- Identify which cell types should be targeted by future therapies.
The full article can be accessed here.
Note: This study was funded by a grant from FCF